Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors

NCT05001347 is registered in ClinicalTrials.gov with I-Mab Biopharma US Limited as lead sponsor.

NCT NCT05001347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05001347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
Lead sponsor
I-Mab Biopharma US Limited
Phase
Phase 2
Overall status
Completed
Start date
November 2, 2021
Completion date
February 8, 2023
Enrollment
25 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal cancer, head and neck cancer, non small cell lung cancer, ovarian cancer, ovarian carcinoma, triple negative breast cancer